Single-Shot ChAd3-MARV Vaccine in Modified Formulation Buffer Shows 100% Protection of NHPs.

Autor: Finch CL; Sabin Vaccine Institute, Washington, DC 20037, USA., King TH; Sabin Vaccine Institute, Washington, DC 20037, USA., Alfson KJ; Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Albanese KA; Battelle Biomedical Research Center, Madison County, OH 43162, USA., Smith JNP; Battelle Biomedical Research Center, Madison County, OH 43162, USA., Smock P; Sabin Vaccine Institute, Washington, DC 20037, USA., Jakubik J; Sabin Vaccine Institute, Washington, DC 20037, USA., Goez-Gazi Y; Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Gazi M; Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Dutton JW 3rd; Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Clemmons EA; Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Mattix ME; Nonclinical Pathology Services, LLC, Medina, OH 44256, USA., Carrion R Jr; Texas Biomedical Research Institute, San Antonio, TX 78227, USA., Rudge T Jr; Battelle Biomedical Research Center, Madison County, OH 43162, USA., Ridenour A; Battelle Biomedical Research Center, Madison County, OH 43162, USA., Woodin SF; Sabin Vaccine Institute, Washington, DC 20037, USA., Hunegnaw R; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Sullivan NJ; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA., Xu R; Clover Biopharmaceuticals, Boston, MA 02109, USA.

Publikováno v: Vaccines [Vaccines (Basel)] 2022 Nov 15; Vol. 10 (11). Date of Electronic Publication: 2022 Nov 15.